Ovarian cancer remains a critical health issue for women globally, primarily due to late diagnoses. On World Ovarian Cancer Day 2026, experts highlighted the absence of a reliable early screening test, attributing this to the disease's biological complexity and the vague symptoms that often accompany it. Unlike cervical and breast cancers, which have established screening methods, ovarian cancer often develops silently, leading to late-stage diagnoses in nearly 70% of cases, as reported by the US National Cancer Institute. Current screening tools, including the CA-125 blood test and transvaginal ultrasound, lack the necessary accuracy for widespread use. Experts emphasize that tumor heterogeneity and the subtlety of early-stage disease present significant challenges in developing effective screening strategies. While promising technologies such as liquid biopsies and AI-driven diagnostics are emerging, they still require extensive validation. Until more reliable screening methods are developed, women with a family history of ovarian or breast cancer are advised to consider specialized surveillance.